Abstract
BACKGROUND: Treatment of chronic hepatitis C virus (HCV) infection was revolutionized within the last years. Interferon free antiviral regimens are not accessible without limitations. Combination of peginterferon/ribavirin with first generation direct acting antivirals is less effective and associated with serious adverse events.
AIM: We have shown that vWF-Ag is associated with portal hypertension and treatment response to PEG/RBV and we evaluated if vWF-Ag is a predictive marker for treatment response and safety in patients with triple therapy.
METHODS: 222 HCV-GT 1 patients and DAA based triple therapy were included in this retrospective, multicenter study.
RESULTS: Median vWF-Ag levels were 167.0% [IQR: 124.0-210.0%]. Significantly higher levels were seen in patients without SVR; median 190% [IQR: 146.0-259.5%] versus SVR: 142.5% [IQR: 114.3-196.8%], p<0.001. Furthermore levels of vWF-Ag were identified as independent predictor of non SVR; (OR: 1.009; 95%CI: 1.016-1.3, p=0.005). In patients with cirrhosis elevated vWF-Ag levels were associated with increased incidence of SAEs (OR: 1.016; 95%CI: 1.004-1.028; p=0.007). Best cut off for prediction of SAEs was vWF-Ag>281.5% with a sensitivity of 78% and a specificity of 90%.
CONCLUSION: Baseline vWF-Ag levels predict outcome of DAA based treatment in HCV-1 patients and identify patients with a risk of SAEs. Therefore vWF-Ag may be an additional marker for selecting patients for interferon free therapeutic regimens.
| Original language | English |
|---|---|
| Pages (from-to) | 1194-1199 |
| Number of pages | 6 |
| Journal | Digestive and Liver Disease |
| Volume | 48 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 01 Oct 2016 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adult
- Antiviral Agents/adverse effects
- Austria
- Biomarkers
- Drug Therapy, Combination
- Female
- Hepacivirus/genetics
- Hepatitis C, Chronic/blood
- Humans
- Interferon-alpha/adverse effects
- Liver Cirrhosis/blood
- Male
- Middle Aged
- Multivariate Analysis
- ROC Curve
- Regression Analysis
- Retrospective Studies
- Ribavirin/adverse effects
- von Willebrand Factor/analysis
Fingerprint
Dive into the research topics of 'von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver